Date:9/7/2012

forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

'/>"/>

SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
3. Perrigo Company To Present At The William Blair Growth Stock Conference
4. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
5. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
6. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
7. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
8. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
9. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
10. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
11. Medical Alarm Provides Investor Update -- Company Surpassing Previous Record Order Levels as Consumer Interest Accelerates